Malignant melanoma

  • B.-R. Balda
  • H. Starz


Malignant melanoma is a malignant tumour originating from the transformation of melanocytes or naevus cells. These cells, arising from the neural crest are not only encountered in the skin and the adjacent mucous membranes, but also in the uvea, retina and central nervous system. Nonetheless, between 85% and 90% of melanomas arise on the outer skin.


Black skin cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further reading

  1. Andreassi L, Balda B-R, Landi G. Current trends in the treatment of melanoma. Skin Cancer 1993; 8: 103–13.Google Scholar
  2. Bachter D, Balda B-R, Vogt H, Büchels H. Die ‘sentinel’ Lymphonodektomie mittels Szintillationsdetektor. Hautarzt 1996; 47: 754–8.PubMedCrossRefGoogle Scholar
  3. Bachter D, Balda B-R, Vogt H, Büchels H. Primary therapy of malignant melanomas: Sentinel lymphadenectomy. IntJDermatol 1998; 37: 278–82.Google Scholar
  4. Balch C, Buzaid AC, Atkins MB etal. A New American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Cancer 2000; 88: 1484–91.PubMedCrossRefGoogle Scholar
  5. Balch C, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635–48.PubMedGoogle Scholar
  6. Balda B-R, Herrmann R. Neoplasien der Haut. In: Huhn D, Herrmann R, eds. Medikamentöse Therapie Maligner Erkrankungen, 3rd edn. Stuttgart: Fischer, 1995: 393–405.Google Scholar
  7. Balda B-R. Die Sentinel-Lymphonodektomie bei malignen Melanomen—mehr als ein Diagnostikum? In: Konz B, Plewig G, eds. Fortschr Dermatol. Darmstadt: Steinkopf, 2002: 7–14.CrossRefGoogle Scholar
  8. Bastian B, LeBoit P, Hamm H, Bröcker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58: 2170–5.PubMedGoogle Scholar
  9. Bastian B, Kashani-Sabet M, Hann H. Gene amplifications characterize acral melanoma and permit detection of occult tumor cells surrounding skin. Cancer Res 2000; 60: 1968–73.PubMedGoogle Scholar
  10. Berger W, Ebling L, Micksche M. Chemoresistance of human malignant melanoma. Cellular Mol Aspects Onkol 1998; 21: 105–10.Google Scholar
  11. Cochran A, Balda B-R, Starz H, Bachter D, Krag DN, Cruse CW, Pijpers R, Morton DL. The Augsburg Consensus. Techniques, lymphatic mapping, sentinel lymphadenectomy, completion lymphadenectomy, cutaneous malignancies. Cancer 2000; 89: 236–41.PubMedCrossRefGoogle Scholar
  12. Elsässer-Beile U, Schöpf E, Neumann HA, Drews H, Hundhammer K, Balda B-R. Rekombiniertes Leukozyten-A-Interferon beim metastasierten malignen Melanom. Dtsch med Wschr 1987; 112: 373–7.PubMedCrossRefGoogle Scholar
  13. Enk AH, Nashan D, Knop J. Therapie von Lungenmetastasen des malignen Melanoms mit inhalativem IL-2. Hautarzt 1997; 48: 894–6.PubMedCrossRefGoogle Scholar
  14. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16: 1743–51.PubMedGoogle Scholar
  15. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol 1996; 132: 444–50.PubMedCrossRefGoogle Scholar
  16. Kirkwood JM, Hunt-Straderman M, Ernstorff MS, Smith TJ. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17.PubMedGoogle Scholar
  17. Krämer K-U, Prang N, Balda B-R. Evaluation of plasma 5-S-cysteinyldopa as a tumor marker of malignant melanoma. Ann Ital Dermatol 1999; 53: 75–9.Google Scholar
  18. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–9.PubMedCrossRefGoogle Scholar
  19. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999; 9: 51–8.PubMedCrossRefGoogle Scholar
  20. Starz H, Balda B-R. Sentinel lymphonodectomy and micromorphometric S-staging, a successful new strategy in the management of cutaneous malignancies. G Ital Dermatol Venereol 2000; 135: 161–9.Google Scholar
  21. Starz H, Balda B-R, Büchels H. Sentinel-Lymphonodektomie bei malignen Melanomen. Eine vorläufige Bilanz aus histomorphologischerGoogle Scholar
  22. Sicht. In: Garbe C, Rassner G, eds. Dermatologie. Leitlinien und Qualitätssicherung für Diagnostik und Therapie. Heidelberg: Springer, 1998; 274–7.Google Scholar
  23. Starz H, Balda B-R, Kramer KU, Büchels H, Wang JH. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91: 2110–21.PubMedCrossRefGoogle Scholar
  24. Starz H, De Donno A, Balda B-R. The Augsburg Experience: Histological Aspects and Patient Outcomes. Ann Surg Oncol 2001; 8 (9S): 48–51.Google Scholar
  25. Starz H, Cochran AJ, Balda B-R. Die SentinelLymphonodektomie aus histopathologischer Sicht. Akt Dermatol 2002; 28: 273–8.CrossRefGoogle Scholar
  26. Volkenandt M, Schmidt M, Konz B, Gummer M, Hein R, Plewig G, Hölzel D. Klinisch-epidemiologische Daten von Patienten mit malignen Melanomen aus dem Bereich des Tumorzentrums München von 1977 bis 1997. Hautarzt 1999; 50: 470–78.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • B.-R. Balda
  • H. Starz

There are no affiliations available

Personalised recommendations